Skip to content

Effectiveness and safety of Apatinib combined SOX regimen for conversion therapy of unresectable advanced gastric cancer

Effectiveness and safety of Apatinib combined SOX regimen for conversion therapy of unresectable advanced gastric cancer

Status
Recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800016138
Enrollment
Unknown
Registered
2018-05-14
Start date
2017-12-28
Completion date
Unknown
Last updated
2018-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric cancer

Interventions

Case series:aptinib+S-1+ oxaliplatin

Sponsors

Yantai Yuhuangding Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18~75 years old; 2. ECOG(Eastern Cooperative Oncology Group) 0~1; 3. Definitely diagnosed gastric adenocarcinoma through Pathology or Cytology with Her2-negative; 4. Expected lifetime acuity =3 months; 5. Without the history of anti-tumor therapy including Radiotherapy, chemotherapy, targeted therapy, immunotherapy 6. Normal hemodynamic indices before the recruitment(including blood cell count and liver/kidney function ). For example: WBC>4.0×10^9/L, NE>1.5×10^9/L, PLT>100×10^9/L, BIL50ml/min using Cockcroft-Gault formula,and Cr=1×ULN; 8. Good cardiac function before the recruitment, no seizure of myocardial infarction in past half years, and controllable hypertension and other coronary heart disease; 9. Not concomitant with other uncontrollable benign disease before the recruitment (e.g. the infection in the kidney, lung and liver); 10. Signed the Informed Consent Form.

Exclusion criteria

Exclusion criteria: 1. Distal metastasis to lung, brain, and bone but liver 2. Her-2 test was positive and willing to receive Hessaitin treatment 3. Operation intolerance due to other uncontrolled diseases(Including atrial fibrillation, angina pectoris, cardiac dysfunction, ejection fraction less than 50%, refractory hypertension, and renal dysfunction) 4. Ever administrated with other drugs(including TCM drugs) before the recruitment, or no guarantee of progress according to the study requirement after recruitment 5. Allergy to the drugs in this protocol 6. Pregnant and lactating women 7. Women at childbearing age and of pregnancy desire during the study 8. Any medical or other condition that in the opinion of the investigator would preclude the subjects participation in a clinical study.

Design outcomes

Primary

MeasureTime frame
radical resection rate;safety;

Secondary

MeasureTime frame
DCR;ORR;

Countries

China

Contacts

Public ContactJiang Lixin

Yantai Yuhuangding Hospital

jianglixin1969@hotmail.com+86 18660568896

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026